Michael Newman
Net worth: 177 890 $ as of 2026-05-30
Net worth: 177 890 $ as of 2026-05-30
Michael James Newman was the founder of Decoy Biosystems, Inc., founded in 2013, where the titles held included President, CEO, CFO, Secretary & Director from 2013 to 2021.
Dr. Newman is the founder of Indaptus Therapeutics, Inc., founded in 2021, holding the title of Chief Scientific Officer since 2021.
Former jobs include Executive Director-Oncology at Novartis Pharmaceuticals Corp.
from 1992 to 1997, Senior Associate Director at Sandoz Pharmaceuticals Corp., Director & Chief Scientific Officer at Intec Pharma Ltd., Executive Vice President-Oncology at Huyabio International LLC, Faculty at Brandeis University from 1984 to 1987, Executive Vice President-Oncology at Ontogen Corp., Executive Vice President-Research & Development at Vaxiion Therapeutics LLC, and Chief Scientific Officer & Vice President-Research at Dihedron Corp.
Education includes undergraduate studies at the University of California San Diego and a doctorate from Harvard Medical School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-01-20 | 101,074 ( 0.09% ) | 177 890 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| INDAPTUS THERAPEUTICS, INC. | Founder | 2021-02-23 |
| Companies | Position | End |
|---|---|---|
Decoy Biosystems, Inc.
Decoy Biosystems, Inc. BiotechnologyHealth Technology Develops toll-like receptor against cancer and provides cancer immunotherapy services | Chief Executive Officer | 2021-07-31 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Corporate Officer/Principal | 1996-12-31 |
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 1986-12-31 |
Intec Pharma Ltd.
Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products to treat neurodegenerative diseases | Chief Tech/Sci/R&D Officer | - |
Huyabio International LLC
Huyabio International LLC Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 12 |
|---|---|
Huyabio International LLC
Huyabio International LLC Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
Ontogen Corp. | |
Sandoz Pharmaceuticals Corp. | |
Vaxiion Therapeutics, Inc.
Vaxiion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dihedron Corp. | |
Intec Pharma Ltd.
Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products to treat neurodegenerative diseases | Health Technology |
Decoy Biosystems, Inc.
Decoy Biosystems, Inc. BiotechnologyHealth Technology Develops toll-like receptor against cancer and provides cancer immunotherapy services | Health Technology |
Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions